References
1. Fukushima T., Tsuji T., Watanabe N., Sakurai T., et al. The current status of inpatient cancer rehabilitation provided by designated cancer hospitals in Japan. Jpn J Clin Oncol. 2021; 51 (7): 1094–9. DOI: https://doi.org/10.1093/jjco/hyab070
2. Silver J.K., Baima J., Mayer R.S. Impairment-driven cancer rehabilitation: an essential component of quality care and survivorship. CA Cancer J Clin. 2013; 63: 295–317. DOI: https://doi.org/10.3322/caac.21186
3. Dong S.T., Butow P.N., Costa D.S., Lovell M.R., Agar M. Symptom clusters in patients with advanced cancer: a systematic review of observational studies. J Pain Symptom Manage. 2014; 48: 411–50.
4. Neo J., Fettes L., Gao W., Higginson I.J., Maddocks M. Disability in activities of daily living among adults with cancer: a systematic review and meta-analysis. Cancer Treat Rev. 2017; 61: 94–106.
5. Omran S., Mcmillan S. Symptom severity, anxiety, depression, self-efficacy and quality of life in patients with cancer. Asian Pac J Cancer Prev. 2018; 19: 365–74.
6. Kasyanenko K.V., Kozlov K.V., Maltsev O.V., Lapikov I.I. et al. Evaluation of the effectiveness of Riamilovir in the complex therapy of patients with COVID-19. Terapevticheskii Arkhiv [Therapeutic Archive]. 2021; 93 (3): 290–294. DOI: https://doi.org/10.26442/00403660.2021.03.200719 (in Russian)
7. Sabitov A.U., Sorokin P.V., Dashutina S.Yu. Experience of the preventive use of the drug Riamilovir in the foci of coronavirus infection (COVID-19). Terapevticheskii Arkhiv [Therapeutic Archive]. 2021; 93 (4): 435–9. DOI: https://doi.org/10.26442/00403660.2021.04.200751 (in Russian)
8. Sabitov A.U., Sorokin P.V., Dashutina S.Yu. The efficacy and safety of Riamilovir in the treatment of patients with COVID-19. Antibiotiki i khimioterapiya [Antibiotics and Chemotherapy]. 2021; 66: 1–2: 33–37. DOI: https://doi.org/10.37489/0235-2990-2021-66-1-2-33-37 (in Russian)
9. WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020; 20 (8): e192–7. DOI: https://doi.org/10.1016/S1473-3099(20)30483-7. Erratum in: Lancet Infect Dis. 2020; 20 (10): e250. PMID: 32539990; PMCID: PMC7292605.
10. Klok F.A., Boon G.J.A.M., Barco S., Endres M., et al. The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19. Eur Respir J. 2020; 56 (1): 2001494. DOI: https://doi.org/10.1183/13993003.01494-2020; PMID: 32398306; PMCID: PMC7236834.
11. Kozlov V.A., Savchenko A.A., Kudryavtsev I.V., Kozlov I.G., et al. Clinical Immunology. Krasnoyarsk: Polikor, 2020: 345 p. DOI: https://doi.org/10.17513/np.438 (in Russian)
12. Kudryavtsev I.V., Subbotovskaya A.I. Application of six-color flow cytometric analysis for immune profile monitoring. Meditsinskaya Immunologiya [Medical Immunology]. 2015; 17 (1): 19–26. DOI: http://dx.doi.org/10.15789/1563-0625-2015-1-19-26 (in Russian)
13. Li G., Fan Y., Lai Y., Han T., et al. Coronavirus infections and immune responses. J Med Virol. 2020; 92 (4): 424–32. DOI: https://doi.org/10.1002/jmv.25685